Last reviewed 2026-04-20 · How we verify

Antizol

Antizol, marketed by Amgen, is a treatment for accidental poisoning by methyl alcohol, currently holding a niche but critical position in this specialized market. The drug's key strength lies in its unique mechanism of action, which provides a rapid and effective antidote for methyl alcohol poisoning. The primary risk to Antizol is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.

At a glance

Approved indications

• Accidental poisoning by methyl alcohol
• Ethylene Glycol Toxicity

Common side effects

• Headache
• Nausea
• Dizziness
• Increased drowsiness
• Bad taste/metallic taste
• Abdominal pain
• Fever
• Pain during Antizol injection
• Inflammation at injection site
• Lumbalgia/backache
• Hangover
• Sinus bradycardia/bradycardia

Serious adverse events

• Multiorgan system failure
• Shock
• Disseminated intravascular coagulation
• Seizure
• Anuria
• Phlebosclerosis
• Eosinophilia/hypereosinophilia
• Lymphangitis
• Anemia
• Decreased appetite

Key clinical trials

• The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients (PHASE1)
• Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose (PHASE2)
• Fomepizole Dosing During Continuous Renal Replacement Therapy (CRRT)
• Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism (PHASE2)
• Specified Drug-use Survey of Fomepizole Intravenous Infusion (All-case Surveillance)
• Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy (PHASE1)
• 4-methylpyrazole and Acetaminophen Metabolism (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.